People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions in their ...

Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative ...

The global Oral Anti-Diabetic Drug market is poised for substantial growth, driven by increasing diabetes cases, advancements ...

Kumamoto University scientists have unveiled a novel compound, HPH-15, with dual effects of reducing blood glucose levels and ...

Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...

Delivering biologics via oral administration represents a growing market that is expected to exhibit 35% CAGR from 2023–2028.